Cargando…

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada

Detalles Bibliográficos
Autores principales:	Gerth, William C, Betschel, Stephen D, Zbrozek, Arthur S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125998/ http://dx.doi.org/10.1186/1710-1492-10-S1-A42

Ejemplares similares

Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
por: Gill, Parwinder K., et al.
Publicado: (2018)

Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG
por: Anterasian, Christine, et al.
Publicado: (2019)

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2017)

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2018)

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
por: Wasserman, Richard L., et al.
Publicado: (2012)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

SCIg vs. IVIg: let’s give patients the choice!
por: Samaan, Kathryn K, et al.
Publicado: (2014)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
por: Suez, Daniel, et al.
Publicado: (2017)

Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy
por: Menzin, Joseph, et al.
Publicado: (2014)

Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Hydroxychloroquine-Induced Myopathy Responding to Intravenous Immunoglobulin (IVIG)
por: Almoallim, Hani, et al.
Publicado: (2023)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
por: Ducruet, Thierry, et al.
Publicado: (2011)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies()
por: Shrestha, Pragya, et al.
Publicado: (2019)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg
por: Beydoun, Said R., et al.
Publicado: (2021)

Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
por: Kwapisz, Dorota, et al.
Publicado: (2023)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Kaarthigeyan, K., et al.
Publicado: (2011)

Aseptic meningitis following intravenous immunoglobulin therapy of common variable immunodeficiency
por: Bhatt, Girish Chandra, et al.
Publicado: (2012)

Does Intravenous Immunoglobulin Therapy Prolong Immunodeficiency in Transient Hypogammaglobulinemia of Infancy?
por: Memmedova, Lale, et al.
Publicado: (2013)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG
por: Hassini, Slim, et al.
Publicado: (2022)

Streptococcus Pneumoniae-Related Hemophagocytic Lymphohistiocytosis Treated with Intravenous Immunoglobulin (IVIG) and Steroids
por: Dumancas, Carissa Y., et al.
Publicado: (2018)

Transient lymphadenopathy during intravenous immunoglobulin (IVIg) in a patient with pemphigus vulgaris
por: Foulad, Delila Pouldar, et al.
Publicado: (2021)

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
por: Schroeder, H. W., et al.
Publicado: (2012)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia
por: Lok, Ker Zhing, et al.
Publicado: (2015)

A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder
por: Rossignol, Daniel A, et al.
Publicado: (2021)

Intravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency
por: Hasegawa, Mizue, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9s4dotkj8c7rqcfki0uggf2vcd